AlphaQuest LLC Has $220,000 Stock Position in Apogee Therapeutics Inc. $APGE

AlphaQuest LLC boosted its holdings in shares of Apogee Therapeutics Inc. (NASDAQ:APGE) by 344.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,073 shares of the company’s stock after buying an additional 3,932 shares during the period. AlphaQuest LLC’s holdings in Apogee Therapeutics were worth $220,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Brooklyn Investment Group acquired a new position in Apogee Therapeutics during the first quarter valued at $42,000. Mirae Asset Global Investments Co. Ltd. raised its position in Apogee Therapeutics by 18.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,779 shares of the company’s stock valued at $77,000 after buying an additional 272 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in Apogee Therapeutics during the second quarter valued at $218,000. Birchview Capital LP acquired a new position in Apogee Therapeutics during the first quarter valued at $299,000. Finally, XTX Topco Ltd raised its position in Apogee Therapeutics by 170.8% during the first quarter. XTX Topco Ltd now owns 17,188 shares of the company’s stock valued at $642,000 after buying an additional 10,840 shares during the period. 79.04% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Apogee Therapeutics

In other news, insider Carl Dambkowski sold 5,110 shares of the stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $39.80, for a total transaction of $203,378.00. Following the transaction, the insider owned 284,733 shares of the company’s stock, valued at approximately $11,332,373.40. This represents a 1.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last quarter, insiders sold 10,560 shares of company stock worth $409,524. Corporate insiders own 42.77% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on APGE shares. Zacks Research lowered Apogee Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 14th. Royal Bank Of Canada initiated coverage on Apogee Therapeutics in a research report on Thursday, September 25th. They issued an “outperform” rating and a $60.00 target price on the stock. Citigroup reaffirmed a “buy” rating on shares of Apogee Therapeutics in a research report on Thursday, August 28th. Wedbush reaffirmed an “outperform” rating and issued a $90.00 target price on shares of Apogee Therapeutics in a research report on Monday, August 11th. Finally, Bank of America upped their target price on Apogee Therapeutics from $78.00 to $87.00 and gave the stock a “buy” rating in a research report on Thursday, August 28th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Apogee Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.00.

Apogee Therapeutics Stock Performance

Shares of NASDAQ APGE opened at $56.59 on Friday. The firm has a market cap of $2.61 billion, a price-to-earnings ratio of -13.70 and a beta of 1.43. The business’s 50-day simple moving average is $43.88 and its 200-day simple moving average is $40.67. Apogee Therapeutics Inc. has a 52 week low of $26.20 and a 52 week high of $63.50.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings data on Monday, August 11th. The company reported ($1.13) EPS for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.10). As a group, equities research analysts forecast that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current year.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.